We report the case of a woman with multiple sclerosis who developed a severe neurological condition following natalizumab (NZB) withdrawal and soon after fingolimod (FTY) initiation. FTY was started 3.5 months after a two-year NZB treatment. Fifteen days later, she suffered partial repetitive seizures followed by a tonicoclonic seizure. This was associated with attention difficulties and an increased asthenia. Brain MRI follow-up disclosed large demyelinating active lesions in favour of disease reactivation. This case suggests that FTY introduction may occur less than three months after NZB withdrawal.
StuveOCravensPDFrohmanEM. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology2009; 72: 396–401.
2.
O’ConnorPWGoodmanAKapposL. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology2011; 76: 1858–1865.
3.
MillerDHKhanOASheremataWA. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2003; 348: 15–23.
4.
BergerJRCentonzeDComiG. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol2010; 68: 409–411.
5.
MiravalleAJensenRKinkelRPImmune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol2011; 68: 186–191.
6.
VellingaMMCastelijnsJABarkhofF. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patient. Neurology2008; 70: 1150–1151.
7.
NaismithRTBourdetteDInterruption of natalizumab therapy for multiple sclerosis: What are the risks?Neurology2011; 76: 1854–1855.
8.
MinJHKimBJLeeKH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler2012; 18: 113–115.
9.
CastropFKowarikMCAlbrechtH. Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence?Neurology2012; 78: 928–930.
